Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical
product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety
of MYCAPSSA™ treatment in patients with acromegaly.